Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in Epidermal Growth Factor Receptor (EGFR) kinase were found to be effective targets in a subset of lung cancer patients.
• The role of kinase fusion genes in lung cancer pathogenesis remained largely unexplored.
• The identification of EML4-ALK fusion kinase in 2007 marked a significant advancement, establishing kinase fusions as a crucial class of targetable oncogenes.

Purpose of the Study:

• To review the discovery of REarrangement during Transfection (RET) fusions.
• To highlight RET fusions as the third identified kinase fusion gene in lung cancer.
• To discuss the significance of kinase fusion genes as oncogenes in lung cancer.

Main Methods:

• Literature review of scientific publications.
• Analysis of genetic data related to lung cancer.
• Focus on the discovery and characterization of fusion genes.

Main Results:

• Epidermal Growth Factor Receptor (EGFR) inhibitors showed efficacy in specific lung cancer subsets.
• The discovery of EML4-ALK fusion kinase revolutionized understanding of lung cancer drivers.
• REarrangement during Transfection (RET) fusions were identified as a third significant kinase fusion in lung cancer.

Conclusions:

• Kinase fusion genes, including RET fusions, are important oncogenic drivers in lung cancer.
• Targetable kinase fusion genes represent a critical area for lung cancer therapy development.
• Further research into fusion oncogenes will likely yield new therapeutic strategies.